144 results about "Treatment dose" patented technology

The invention discloses an image segmentation method for evaluating a hepatocellular carcinoma neutron therapy dose, and relates to the technical field of neutron therapy. A 3D U-Net GAN network model is trained through a medical image data set; a generator model and a discriminator model in a 3D U-Net GAN network model are alternately trained by using a real image and a false image randomly generated by the generator model, so that the trained generator model can generate a segmentation result which is more accurate and rich in details for a medical image; the trained discriminator model can more accurately evaluate the authenticity of the output of the generator model, and the trained network can accurately reflect the anatomical structure of the patient, the distribution condition of 10B in the body and the radionuclide dynamics condition when segmenting the medical image, so that the information in the medical image can be accurately and fully displayed, and the medical image segmentation efficiency can be improved. The application is convenient.

The invention relates to the technical field of nasopharyngeal carcinoma radiotherapy, in particular to a nasopharyngeal carcinoma radiotherapy dose automatic prediction method based on deep learning, and the method comprises the following steps: S1, analyzing obtained original data; s2, writing a program to pre-process all the original data in batches; s3, calculating a corresponding dose volume histogram according to the anatomical contour and the patient dose distribution; and S4, inputting the preprocessed data into a designed deep learning model for dose distribution training and prediction, and comparing with an existing dose prediction method to verify the innovativeness and feasibility of the scheme. Dose prediction is automatically carried out through the deep learning model, manual rule design is not needed, high-quality dose distribution can be rapidly generated, batch preprocessing is carried out on all original data, dose distribution training and prediction are carried out by inputting the data into the designed deep learning model, the calculation performance is improved, and the method is suitable for large-scale popularization and application. And the training and reasoning efficiency is improved.

The invention discloses a close-range radiotherapy plan optimization method and device based on a cumulative dose target. The method comprises the following steps: S1, importing current treatment data; s2, leading in a preorder treatment image and performing deformation registration to the current image; s3, mapping the preorder treatment dose to the current treatment image to serve as the background dose of the current treatment; s4, converting the dose data mapped to the current treatment image by the preorder treatment into a bioequivalent dose; s5, on the basis of the sketching data of the current treatment image and with reference to the clinical endangered organ dose limit value requirement, key area generation is carried out on each endangered organ; s6, based on the preorder treatment dosage, generating a corresponding organ-endangered high-risk dosage area and a target area insufficient area according to each organ-endangered dosage limit value and the target area prescription dosage; and S7, optimizing the treatment plan, and optimizing the treatment plan by taking the preorder treated dose and the sum of the planned dose to be optimized at the time to meet the clinical requirement as a target.

The invention relates to a self-adaptive radiotherapy dose optimization method and device and a storage medium, which are used for optimizing dose distribution in radiotherapy. Through combination of deep reinforcement learning (DRL) and a heuristic algorithm (a particle swarm optimization algorithm), the method maximizes the dose of a tumor area, and protects surrounding normal tissues at the same time. Firstly, an anatomical structure and a tumor area of a patient are extracted through medical image data, and initial dose distribution is generated; then, the deep reinforcement learning agent adjusts dose distribution according to the dynamic anatomical change of the patient, a heuristic algorithm is further optimized, and a local optimal solution is avoided; real-time feedback in the treatment process is used for adjusting dose distribution, and accuracy and timeliness of a treatment scheme are ensured. Finally, the generated optimal dose distribution scheme is provided for a clinician to refer, dose maximization of the tumor area is ensured, and normal tissue is protected. According to the method, the precision and effect of radiotherapy are improved, and a personalized treatment scheme is provided.

Methods, devices, and systems for treating a region of interest (ROI) of skin of a subject or patient in need thereof are disclosed. Such a method of treating a ROI, in some embodiments, comprises irradiating a test region (TR) of the skin with a sub-therapeutic dose of electromagnetic radiation or with a series of sub -therapeutic doses, determining a tissue response of the TR, and generating one or more therapeutic dose parameters based at least in part on the tissue response of the TR. In some embodiments, the method further comprises irradiating the ROI with one or more therapeutic doses of electromagnetic radiation in accordance with the one or more therapeutic dose parameters.

A neural network is trained using a training corpus having a plurality of information features, each of the information features including both a reference radiation treatment dose and at least one corresponding post-treatment patient datum. By one approach, the at least one corresponding post-treatment patient datum comprises patient imagery such as, but not limited to, one or more computed tomography images. That trained neural network facilitates radiation treatment planning by generating resultant treatment efficacy probability information and resultant treatment complications probability information.

Electrically neutral complex compounds of formula I including any stereoisomer or E / Z isomer thereof wherein: M is Fe < 2 + >, Ru < 2 + >, Os < 2 + >, Co < 3 + >, Rh < 2 + >, Rh < 3 + >, Ir < 3 + >, Ni < 2 + >, Pd < 2 + >, Pt < 2 + > or Pt < 4 + >, in particular Ru < 2 + >; t and T'are H or (C1-C3)-alkyl; lig is a bidentate ligand, in particular 2, 2 '-dipyridyl (bpy) or 4, 7-diphenyl-1, 10-phenanthroline (BPhen); and A is an anion from a pharmaceutically acceptable acid, the electrically neutral complex compounds of formula I are useful in human therapy, in particular as photosensitizers (PS) in photodynamic therapy (PDT) of cancer, skin diseases, fungal infections or microbial infections. They are almost non-toxic under dark conditions at therapeutic doses and exhibit good to excellent photoactivity under hypoxic conditions. They can be used for PDT treatment of deep hypoxia tumors by using light within a far-infrared to near-infrared light treatment window.

The inhalation suspension preparation containing the SGC receptor stimulant comprises the SGC receptor stimulant with an effective therapeutic dose or pharmaceutically acceptable salt of the SGC receptor stimulant, and pharmaceutically acceptable auxiliary materials of the suspension preparation, the pharmaceutically acceptable auxiliary materials of the suspension preparation comprise at least one of a surfactant, a pH regulator, an osmotic pressure regulator and a metal complexing agent; the inhalation suspension preparation containing the riociguat shows good lung absorption efficiency, is beneficial to reaching the same or better treatment level by reducing the administration dosage, can directly act on a diseased region through an administration route, takes effect more quickly compared with oral administration of the riociguat, and has a good application prospect. Gastrointestinal discomfort and systemic hypotension side effects caused by gastrointestinal tract contact and absorption entering a circulatory system can be avoided, the treatment cycle of an oral dosage form dosage titration administration scheme is shortened, and a better treatment scheme is provided for relieving dyspnea and syncope symptoms of pulmonary hypertension patients treated at home.

Techniques for adjusting radiotherapy treatment for a patient in real-time are provided. The techniques include obtaining a training patient anatomy at a first time within a training radiotherapy treatment fraction after a training radiotherapy treatment dose has been delivered by a radiotherapy device; computing a deviation between the training patient anatomy at the first time and reference training patient anatomy during the training radiotherapy treatment fraction, wherein the reference training patient anatomy indicates a prescribed training dose parameter to be delivered within the training radiotherapy treatment fraction; applying the computed deviation to a machine learning model to estimate one or more intra-fraction radiotherapy treatment parameters of a function that provides a radiotherapy device parameter adjustment based on the one or more intra-fraction radiotherapy treatment parameters; and training the machine learning model to establish a relationship between the computed deviation and the one or more intra-fraction radiotherapy treatment parameters.

Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.

The present application relates to the field of intelligent medical treatment, in particular to a tumor treatment dosing regimen Pareto optimization method based on forward-backward stochastic differential equation. The present application unifies the terminal tumor load, dosing cost and treatment risk into the same stochastic control framework, can establish the Pareto optimality condition corresponding to the nonlinear model, and further converts into the implementable closed-loop state feedback control law in the LQ case. Through the combination with the numerical example and the Pareto frontier analysis, an implementable, interpretable and scalable technical path is provided for the multi-objective individualized treatment regimen design, which can solve the problem that the existing technology is difficult to uniformly process the terminal therapeutic effect, dosing consumption and cumulative risk, and difficult to obtain the implementable closed-loop feedback strategy under the forward-backward stochastic control framework.

The invention provides a BNCT treatment dose accelerated calculation method, a terminal and a treatment planning system. The method comprises the steps of equally dividing each voxel block into a first voxel block and a second voxel block based on a three-dimensional coordinate of each voxel block in a voxel model; alternately iteratively executing the parallel computing process of the first voxel block and the parallel computing process of the second voxel block on the basis of a pre-constructed computing dependency relationship, and obtaining the neutron ejection flow and the neutron flux of each voxel block until an iteration stop condition is met; wherein the dependency calculation relation includes that parallel calculation of the first voxel block depends on neutron outgoing flow of the second voxel block, and parallel calculation of the second voxel block depends on neutron outgoing flow of the first voxel block; and calculating the BNCT therapeutic dose based on the neutron flux of each voxel block. According to the method, on the premise of strictly guaranteeing the calculation precision, a large-scale parallel calculation task set can be formed, the iteration convergence period and the overall calculation time consumption are reduced to the maximum extent, and the requirement for clinically and rapidly calculating the BNCT treatment dose is met.

The present invention concerns dosimetry-related uses and methods that rely on a metastable technetium-99 (99mTc) radionuclide-comprising (dosimetric) radioimmunoconjugate (RIC) to evaluate or establish therapeutic doses of yttrium-90 (90Y) radionuclide-comprising (therapeutic) radioimmunoconjugates, both RICs targeting the same molecular target. More specifically, radioimmunoconjugates that comprise a CD66-binding component are used. Another aspect of the invention relates to Single Time Point dosimetry procedures replacing the need for traditionally used Multiple Time Point dosimetry procedures for yttrium-90 (90Y) radionuclide-comprising radioimmunoconjugates.

The endovenous treatment assembly comprises a wire element (1) for delivering treatment doses, such as for example an optical fiber, which is flexible and capable of being inserted, over part of its length, longitudinally into a vein (V), and a positioning and guiding part (2A), which is integral with the wire element (1) for delivering treatment doses so as to allow manipulation of the wire element (1) for delivering treatment doses by means of this part (2A), the wire element (1) for delivering treatment doses being able to slide in the direction of its length relative to said part (2A);the part (2A) comprises first means for guiding in translation a first portion (110a) of the wire element (1) for delivering treatment doses in the direction of its length and first mechanical assembly means (202, 203) allowing its removable mounting relative to a drive system (4), such that said first portion (110a) of the wire element (1) for delivering treatment doses can be positioned and guided by means of this part (2A) relative to the drive means of the drive system (4) for driving the wire element (1) for delivering treatment doses in the direction of its length at least in a first direction (R).;

The present invention provides a device, system, and method of using the same that can safely and effectively transmit therapeutic or germicidal ultraviolet (UV) radiation, such as UVC radiation or UVA radiation. [Solution] The treatment device comprises a base component and a head component. The head component has a distal portion and a proximal portion. The distal portion of the head component is configured to contact the target eyelid, and the proximal portion is configured to be attached to the base component. The distal portion of the head component is configured to transmit a therapeutic dose of energy from a plurality of energy sources, including an ultraviolet C (UVC) radiation source, an infrared (IR) radiation source, and an ultrasonic source. The plurality of energy sources are configured to transmit a therapeutic dose of energy to the target eyelid at a predetermined output when the distal portion of the head component contacts the eyelid.

Hydration of a larynx and / or vicinity with a composition comprising a salt formulation (e.g., CaCl2, MgCl2, KCl and / or NaCl) can achieve prophylactic and / or therapeutic effects (e.g., cough suppression, improving voice quality, increasing pulse oxygen saturation and / or increasing mucosal vaccination effectiveness). The composition is administered as dry particles (e.g., aerosol) or as a liquid (e.g., solution, aerosol). The liquid can have a pH of 7.0 up to around 10.0, or preferably around 7.5 up to around 9.5, or more preferably around 8.0 up to around 9.0, or even more preferably 8.0 to 8.5 or most preferably around 8.0. The droplets can have a mass median aerodynamic diameter from approximately 8 μm to approximately 15 μm or from approximately 15 μm to approximately 500 μm. A therapeutic dose (e.g., 0.5 mg to 4.0 mg mass of salt) is administered in response to an indication. Such can employ an osmolitically active composition.

The invention belongs to the technical field of biological medicine, and particularly relates to application of coniferyl aldehyde in preparation of anti-cancer drugs. The invention discloses application of coniferyl aldehyde in preparation of anti-cancer drugs, coniferyl aldehyde can significantly inhibit invasion and migration ability of hepatocellular carcinoma cells, cancer cells cannot break through primary parts through key links such as interference of movement and adhesion of the cancer cells and degradation of extracellular matrixes, invasion of tumors to surrounding tissues is reduced, and the anti-cancer effect is improved. The occurrence rate of remote metastasis is reduced, the non-metastasis lifetime of the patient is prolonged, and more treatment time and survival opportunities are won for the patient; a large number of cell experiments and animal experiments prove that the medicine has no obvious liver and kidney toxicity under the treatment dosage, the tolerance of a patient to treatment is improved, the smooth proceeding of the treatment process is guaranteed, and the living quality of the patient is effectively improved.

The invention discloses an image segmentation method for evaluating a non-small cell lung cancer neutron treatment dose, and relates to the technical field of neutron therapy, and the method comprises the steps: carrying out the training of a 3D U-Net network model through a medical image data set, updating the network parameters and hyper-parameters in the 3D U-Net network model, so as to obtain a trained 3DU-Net network model, and carrying out the evaluation of the neutron treatment dose of the non-small cell lung cancer. In the aspect of processing three-dimensional volume data in an image, information of a space direction can be better reserved, segmentation of a three-dimensional structure can be more accurately carried out, and the segmentation form can accurately reflect an anatomical structure of a patient, a distribution condition of 10B in a body and a radionuclide dynamics condition. Therefore, the information in the medical image can be accurately and fully displayed, and application is facilitated.

The invention belongs to the technical field of biological medicine, and particularly relates to a heparin small molecule antagonist-quaternary ammonium salt macrocyclic compound and a preparation method thereof. The quaternary ammonium salt macrocyclic compound disclosed by the invention comprises three piperazine functionalized quaternary ammonium salt macrorings and four methylated quaternary ammonium salt macrorings; the quaternary ammonium salt macrocyclic compound can be used for preparing a heparin small molecule antagonist. The compound shows excellent antagonism efficiency on ungraded heparin and low-molecular-weight heparin, and shows a wide therapeutic dose window; and the antagonism efficiency and dosage window of the protamine are superior to those of clinically used protamine. Besides, in-vivo and in-vitro safety evaluation proves that the quaternary ammonium salt macrocycle has good biocompatibility, and shows clinical transformation potential as a protamine substitute as a small molecule antagonist.

The instant application describes improved methods and compositions for the systemic delivery of therapeutic exosomes to a subject in need thereof. In certain embodiments, the current invention reduces the amount of exosomes delivered to liver, spleen and combinations thereof to allow greater distribution to other areas of the body such as, but not limited to, the brain, pancreas, lung, kidney, muscle. In certain embodiments, the methods involve the injection of one or multiple doses of non-therapeutic exosomes prior to the injection of a suitable therapeutic dose of exosomes with a therapeutic payload. Also included are methods to improve immune clearance of exosomes in subjects by inhibiting phagocytosis.

The utility model discloses a cell therapy drug delivery device stable in drug delivery, which relates to the technical field of drug delivery devices and comprises a drug storage tube with a drug storage space and a drug delivery head detachably connected to the front end of the drug storage tube; the piston rod is of a hollow structure and can slide in the axial direction of the medicine storage pipe, and the end, extending into the medicine storage pipe, of the piston rod is connected with a piston head. The threaded rod is rotationally arranged in the piston rod, and the outer wall of the threaded rod is in threaded connection with a threaded sleeve capable of sliding in the axial direction of the piston rod; the movable plate is connected to the interior of the medicine storage pipe in a sliding mode, a plurality of through holes are formed in the movable plate, and the front end of the threaded sleeve penetrates through the piston head and is fixedly connected with the center of the movable plate. According to the utility model, the medicine can be stirred and disturbed before being used, so that the uniform distribution of cell exosomes in a target area in the treatment process is ensured, the adverse reaction or invalid treatment condition caused by over-high or over-low local concentration is avoided, and the stability and the accuracy of therapeutic administration are remarkably improved.

It is disclosed herein that that certain alkylphosphocholine analogs are preferentially taken up by malignant pediatric tumor cells. The alkylphosphocholine analogs are compounds having the formula:or salts thereof, wherein n is an integer from 12 to 24; and R2 is —N+(CH3)3. The compounds can be used to treat pediatric solid tumors or to detect pediatric solid tumors. In therapeutic treatment, R1 includes a radioactive iodine isotope that locally delivers therapeutic dosages of radiation to the malignant pediatric tumor cells that preferentially take up the compound. In detection / imaging applications, R1 includes a detection moiety, such as a fluorophore or a radioactive iodine isotope.

The invention provides a method of assessing the appropriate therapeutic dose of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid to administer to a patient in need thereof, comprising the steps of:(i) testing whether or not the patient has the poor metabolizer genotype; and(ii) if the patient does not have the poor metaboliser genotype, administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at the standard therapeutic dose; and(iii) if the patient does have the poor metaboliser genotype, either(a) administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at a therapeutic dose below that of the standard therapeutic dose; or(b) not administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient.

The invention relates to a treatment station (20) for treating cans (4) and kegs (3), comprising at least one treatment head (1) for internal cleaning and / or filling of a keg (3) and at least one filling element (5) provided above the treatment head (3) for filling a can (4) with a liquid filling material, wherein the filling element (5) is height-adjustable and designed to press the keg (3) against the treatment head (1) during its internal cleaning and / or filling.

To provide techniques for predicting the risk of a subject experiencing a cytokine release syndrome of at least a threshold grade subsequent to receiving a treatment.SOLUTION: A risk may be predicted based on, for example, a set of baseline characteristics, a risk-score generation model, an on-treatment cytokine level, and / or a treatment dosage. The risk may be used to generate an output corresponding to a recommendation as to whether to monitor the subject via in-patient monitoring.SELECTED DRAWING: Figure 1

A method is provided to modulated vascular adaptation within a tumor so that therapy uptake is increased. The method includes providing a pressure directed therapy system having an infusion lumen, an occluder, a pressure sensor to sense pressure distal of the occluder. The distal end of the system is advanced to a target artery of an organ. The pressure in the target artery is reduced by expanding the occluder at the distal end of the system. Then, the therapy is infused through the infusion lumen and into the target artery. Upon sensing decreased pressure and thus vessel adaptation, infusion is stopped until vessel re-adaptation occurs. Then infusion resumes. The infusion continues in a cycle of therapy infusing, sensing pressure and determining vessel adaptation, waiting, and resuming once re-adaptation occurs until the therapy dose is delivered to the patient.

Systems and methods are disclosed for treating back pain associated with a vertebral body of a patient. The system may include an external energy source configured to be positioned at a location external to the body of the patient, a linear configured to drive translation of the external source in one or more axes, a computer coupled to the external source and linear drive and programming executable on said computer for determining a target treatment site within or near the vertebral body based on acquired imaging data, positioning a focal point of the external energy source to substantially coincide with the target treatment site, and delivering a treatment dose of therapeutic energy at said target treatment site, wherein the treatment dose is configured to modulate a nerve within or near the vertebral body.

Methods and apparatus (e.g., devices, systems, etc.) for applying a therapeutic dose of electrical energy from a nerve sheath to a nerve to modulate neurological function, including mitigating pain, may include using a normalized therapeutic dose value (or range of values) indicative of a target therapeutic charge dose to be applied. The devices and methods may determine a parameter of the applied energy using an impedance value of the nerve at the nerve sheath and a cross-sectional area of a region of the nerve at least partially surrounded by the nerve sheath in combination with a target normalized therapeutic dose value (s). In particular, the parameter may be a parameter required to achieve high frequency nerve block at a target normalized therapeutic dose value (s).

Systems, devices, and techniques are disclosed for differentiating a therapeutic dose and a priming event to properly administer medication to patients. In one example aspect, a method for differentiating therapeutic doses and priming events in administering a medication to a patient includes determining a time window for monitoring dispensing of the medication by an injection pen device. Multiple dispense events each releasing an amount of the medication occur in the time window. The method also includes classifying dispense events prior to a last dispense event in the time window as priming events or therapeutic doses and designating the last dispense event in the time window as a therapeutic dose for facilitating calculation and tracking of a dosage amount for the patient.

The invention relates to the technical field of intelligent medical control and low-temperature plasma medical application, in particular to an intelligent decision-making system for CAP treatment of nephropathy skin complications based on multi-parameter dynamic monitoring. Comprising a multi-modal physical sign acquisition module which is used for acquiring multi-dimensional physiological characterization signals of local tissues and synchronously acquiring periodic metabolism interference data containing dialysis time sequence information; the tolerance threshold inversion module is used for obtaining a local tissue oxidation-reduction tolerance threshold through inversion by using a tissue oxidation-reduction tolerance calculation model; the dynamic interference compensation module is used for generating a real-time safety boundary threshold value; the adaptive strategy generation module is used for generating candidate treatment control strategies by using a deep reinforcement learning algorithm; the risk boundary control module is used for calculating an expected oxidative stress level, if the expected oxidative stress level is larger than or equal to a real-time safety boundary threshold value, blocking or degrading operation is executed, and otherwise, a final treatment instruction is output; the therapeutic dose control precision is improved to the physiological response level, and the iatrogenic skin necrosis risk is effectively avoided.